Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 6/20 | 0.51 |
| ▸ | ACHE | P22303 | 6/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11795691 | 0.87 | ACHE (0.48) | BCHEACHESMN1; SMN2FAAHPTGS2 | |
| SCHEMBL18306927 | 0.86 | ACHE (0.71) | BCHEACHEFAAH | |
| SCHEMBL12043574 | 0.86 | ACHE (0.71) | BCHEACHEFAAH | |
| SCHEMBL5933261 | 0.83 | ACHE (0.71) | BCHEACHESMN1; SMN2FAAHALDH1A1 | |
| SCHEMBL29358693 | 0.83 | ACHE (0.71) | BCHEACHESMN1; SMN2FAAHALDH1A1 | |
| SCHEMBL25820322 | 0.81 | ACHE (0.54) | BCHEACHESMN1; SMN2FAAHALDH1A1 | |
| SCHEMBL5702187 | 0.80 | LMNA (0.59) | FAAHALDH1A1KMT2A | |
| SCHEMBL17026959 | 0.80 | ACHE (0.58) | BCHEACHESMN1; SMN2FAAHALDH1A1 | |
| SCHEMBL5702214 | 0.80 | MTNR1B (0.56) | — | |
| SCHEMBL5702146 | 0.80 | CYP3A4 (0.59) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219927-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219927-A1 | AKT3 MODULATORS | AKT3, AKT2, PIK3CA | BCHE 3202/4885ACHE 4354/4885SMN1; SMN2 2169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.